---
title: "10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3~4%)에 따른 생검 누락 때문으로 보이며, 약효 문제로 단정하기 어렵다. — 하나증권 — DecisionGateway"
description: "statement by 하나증권, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1ceb7-d008-770c-b891-9dbdfbc76586"
meta:
  "og:description": "statement by 하나증권, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3~4%)에 따른 생검 누락 때문으로 보이며, 약효 문제로 단정하기 어렵다. — 하나증권 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3\~4%)에 따른 생검 누락 때문으로 보이며, 약효 문제로 단정하기 어렵다.**

A statement by [**하나증권**](https://dgw.tmarket.io/actors/01a1cea2-176c-7cf2-87ea-9ed64a8130ca). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3\~4%)에 따른 생검 누락 때문으로 보임(약효 문제라 단정하기 어려움)*

hanaresearchPublished 2026-11-08 [ Read source](https://t.me/hanaresearch/20910)

[**하나증권 dossier **](https://dgw.tmarket.io/actors/01a1cea2-176c-7cf2-87ea-9ed64a8130ca)

## **Related claims**

[**에피노페그듀타이드 10mg은 섬유화 개선 외 모든 항목에서 통계적 유의성을 충족했고, 보수적인 mITT 분석에서도 의미 있는 결과를 보였다.**하나증권 · statement](https://dgw.tmarket.io/claims/01a1ceb7-cff0-71a7-a8d3-66029cb5c55b) [**The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad) [**In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6d1-7aec-8105-c4689a803513) [**It is impossible to confirm the reliability of the figures.**thebell\_io · statement](https://dgw.tmarket.io/claims/01a1cb95-ab3f-7cde-9baa-d9ee88955350) [**This mechanism has proven its effectiveness in practice, and its active use is constantly expanding.**Михаил Мишустин · statement](https://dgw.tmarket.io/claims/01a1ce93-3811-7451-96b8-2d4558ca57eb) [**The confidence improvement follows three consecutive readings of deterioration.**analisisbankinter · statement](https://dgw.tmarket.io/claims/01a1cc23-a41a-76ce-8d1e-7aacdcade751)

## **More claims by 하나증권**

[**The report reviewed trends and major economic indicators in the U.S. and Chinese stock markets and analyzed valuations and trends by global sector.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b231-7d52-805c-3f604b6a5af0) [**The U.S. should watch AI-related regulation and volatility in the semiconductor sector, while for China domestic demand stimulus and policy effects will be key to a sustained rebound.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b21a-7518-829b-60cdc773571a) [**This report is a weekly report covering global sector trends and indicators rather than a single earnings estimate for an individual company, and it does not provide annual aggregate earnings figures.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b20e-78ef-8998-71366dda0c35) [**An approach centered on core theme ETFs such as generative AI, semiconductors, quality and cybersecurity, and on major big tech stocks, remains valid.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b203-77a2-bb21-b5002bb38a65) [**Ahead of Nvidia's earnings release on 11/18, market attention is focused on Blackwell demand and next-generation GPU supply outlook.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b1f8-780c-a428-efe4735941fd)

[All claims by 하나증권](https://dgw.tmarket.io/claims?claimant_id=01a1cea2-176c-7cf2-87ea-9ed64a8130ca)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 3,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-d008-770c-b891-9dbdfbc76586#webpage","@type":"WebPage","description":"statement by 하나증권, recorded recently — verbatim quote and source citation.","name":"10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3~4%)에 따른 생검 누락 때문으로 보이며, 약효 문제로 단정하기 어렵다. — 하나증권 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1ceb7-d008-770c-b891-9dbdfbc76586","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-d008-770c-b891-9dbdfbc76586#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1ceb7-d008-770c-b891-9dbdfbc76586"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-d008-770c-b891-9dbdfbc76586#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3~4%)에 따른 생검 누락 때문으로…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-d008-770c-b891-9dbdfbc76586#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-08","isBasedOn":"https://t.me/hanaresearch/20910","text":"10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3~4%)에 따른 생검 누락 때문으로 보임(약효 문제라 단정하기 어려움)","url":"/claims/01a1ceb7-d008-770c-b891-9dbdfbc76586","spokenByCharacter":{"@type":"Person","name":"하나증권","@id":"/actors/01a1cea2-176c-7cf2-87ea-9ed64a8130ca"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.